Fatima Sabiha, Al-Mohaimeed Noura, Al-Shaikh Yazeed, Tyagi Poonam, Banu Naheed, Hasan Shirin, Arjumand Sadia
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, P.O. Box 10219, Riyadh, Saudi Arabia.
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, P.O. Box 10219, Riyadh, Saudi Arabia.
Food Chem Toxicol. 2016 Aug;94:213-20. doi: 10.1016/j.fct.2016.05.023. Epub 2016 Jun 3.
Cisplatin (CP), a platinum based anticancer drug is used as one of the first-line therapy for the treatment of different types of solid tumors. However, CP-induced side effects particularly, nephrotoxicity is a major concern. A single nephrotoxic dose (7 mg/kg body weight) of CP was administered in rats with or without, pre and post combined multidoses of epigallocatechin gallate (EGCG) and coenzyme Q10 (CoQ10) (15 and 5 mg/kg body weight respectively). CP administration resulted in marked increase in the nephrotoxic parameters with alterations in the oxidative and nitrosative stress markers. The concentration of inflammatory, as well as apoptotic markers were markedly up-regulated in the kidney of the CP-treated group. Furthermore, CP resulted in histological injury in the renal tissues. Combined antioxidant treatment significantly (p < 0.01) attenuated CP-induced oxidative stress, nitrosative stress, inflammatory and apoptotic parameters. Moreover, an improvement in the histopathological changes confirmed the nephroprotective effect of antioxidant treatment. In conclusion, our study indicates that the combinatorial multidoses of EGCG and CoQ10 ameliorate the cisplatin-mediated pathogenesis by improving renal oxidative/nitrosative status, inflammation and apoptosis and thus can be used as a promising protective agent to increase the efficacy of the drug by minimizing its major side effect i.e. nephrotoxicity.
顺铂(CP)是一种铂类抗癌药物,用作治疗不同类型实体瘤的一线疗法之一。然而,CP引起的副作用,尤其是肾毒性是一个主要问题。对大鼠给予单次肾毒性剂量(7毫克/千克体重)的CP,同时分别在给药前和给药后联合给予多剂量的表没食子儿茶素没食子酸酯(EGCG)和辅酶Q10(CoQ10)(分别为15毫克/千克体重和5毫克/千克体重)。给予CP导致肾毒性参数显著增加,氧化和亚硝化应激标志物发生改变。在CP治疗组的肾脏中,炎症标志物以及凋亡标志物的浓度显著上调。此外,CP导致肾组织出现组织学损伤。联合抗氧化剂治疗显著(p<0.01)减轻了CP诱导的氧化应激、亚硝化应激、炎症和凋亡参数。此外,组织病理学变化的改善证实了抗氧化剂治疗的肾保护作用。总之,我们的研究表明,EGCG和CoQ10的联合多剂量通过改善肾脏氧化/亚硝化状态、炎症和凋亡来减轻顺铂介导的发病机制,因此可以用作一种有前景的保护剂,通过最小化其主要副作用即肾毒性来提高药物疗效。